HRT and Migraines: Friend or Foe?

Two women can be given the same hormone at the same dose and one will report her migraines halved while the other says they got worse. That looks like unpredictability. It usually is not. The single fact that explains most of it is that estrogen-related migraine is triggered by the fall in estrogen rather than by the level, which means the route of delivery and whether the regimen has off-weeks matter more than the number on the prescription.

Why the drop, not the level

The trigeminovascular system is the circuit that generates migraine pain, and its excitability is sensitive to estrogen. Estrogen influences serotonergic tone and the signalling that sensitises trigeminal neurons; when it withdraws quickly, the threshold for setting that circuit off falls with it.

The classic demonstration is old and still the clearest. Women with menstrual migraine were followed through the cycle, and attacks clustered around the premenstrual estrogen fall rather than at any particular absolute level — and giving estradiol to blunt that fall delayed the attack (Somerville, Neurology 1972). It is the gradient that matters, not the height.

This is why "does estrogen cause migraines?" is the wrong question. Steady estrogen is protective for many women. Estrogen that rises and falls sharply is provocative. The same hormone does both things depending on how it is delivered.

Why they get worse in the forties

Many women find their migraines intensify in their late thirties and forties, often after years of relative stability, and often before any of the more recognised menopausal symptoms appear.

The reason follows directly from the mechanism. Perimenopause is not a smooth decline — it is erratic. Cycles become irregular, estradiol swings higher than it ever went premenopausally and then falls further and faster. Bigger drops, more often, mean more triggered attacks. Headache frequency is measurably higher through this window than before it (Martin et al., Headache 2016).

Two other perimenopausal changes stack on top: disrupted sleep, which is one of the more reliable migraine triggers in its own right, and the falling progesterone that contributes to it. The perimenopause guide covers the wider picture.

Why steady delivery usually helps

Transdermal estradiol — patch, gel or cream — is absorbed through the skin into the circulation continuously, producing a comparatively flat level with little peak-to-trough movement across the day. Flat is exactly what a system triggered by gradients wants. Percutaneous estradiol used to prevent the perimenstrual fall reduced attacks in placebo-controlled work decades ago (de Lignières et al., BMJ 1986), and the finding has been reproduced with gel in menstrual migraine specifically (MacGregor et al., Neurology 2006).

The second variable is just as important and gets less attention: continuous rather than cyclical. A cyclical regimen with a scheduled off-week rebuilds the exact estrogen withdrawal that triggers attacks, once a month, on purpose. For a woman whose migraines are hormonally driven, that is the least helpful pattern available. Continuous dosing removes the cliff.

Why oral can make it worse

Oral estradiol is swallowed, absorbed, and passes through the liver before reaching the circulation. Two consequences follow.

The first is pharmacokinetic: a once-daily tablet produces a daily rise and fall, a repeating gradient, in a woman whose headaches are triggered by gradients. For some women that is enough to keep attacks going on a dose that looks perfectly reasonable on paper.

The second is hepatic. First-pass metabolism changes the liver's production of clotting factors in a way that transdermal delivery does not, and venous thromboembolism risk tracks the oral route rather than the transdermal one (Canonico et al., Circulation 2007). That matters most in the group discussed next.

Migraine with aura is a separate conversation

Migraine with aura carries a modest increase in ischaemic stroke risk on its own, independent of any hormone therapy (Schürks et al., BMJ 2009). Historically this produced blanket caution about giving any estrogen to any woman with aura, and that caution has since been unpicked into something more useful.

The distinction that matters is between contraceptive-dose synthetic estrogen and menopausal-dose estradiol, and between oral and transdermal. Combined hormonal contraceptives in women with aura are where the stroke concern is strongest and where specialist consensus advises against use (European Headache Federation consensus, J Headache Pain 2017). Menopausal hormone therapy is a different exposure, and transdermal delivery avoids the hepatic effects that drive much of the clotting concern.

That last row is not a formality. Aura appearing for the first time in a woman who has never had it is a change that needs a clinician's eyes on it rather than a dose adjustment.

How to run the trial properly

Whether hormone therapy is appropriate at all is a physician's decision made after a full history — HRT for women and when to start cover how that evaluation is structured. Assuming it is, the details that decide whether migraines improve are these:

• Transdermal, not oral, where migraine is a significant part of the picture
• Continuous, not cyclical, so no scheduled withdrawal is engineered into the month
• Start low and titrate slowly. A large step up is itself a change in gradient, and changes provoke attacks in both directions
• Oral micronised progesterone alongside estradiol if the uterus is intact, taken at night, where it also tends to help sleep — see progesterone for sleep and mood
• Keep a headache diary for 8-12 weeks before and after, recording days with headache rather than impressions

The diary is the part people skip and the part that decides the answer. Migraine frequency is naturally variable month to month, and memory reliably over-weights the recent bad week.

What to expect, and when to judge it

Expect the first four to six weeks to be uninformative. Levels are still settling, and a proportion of women get a temporary increase in headache days while they do — the system is being asked to adapt to a new steady state, and the adaptation itself is a change.

The useful comparison is headache days per month across three months against the three before starting. If frequency has fallen, that is the answer. If it is unchanged, ask in order: is this transdermal, is it continuous, is the dose stable, is sleep being addressed. If it has clearly worsened on a steady transdermal regimen, hormones are probably not the driver and the search should move elsewhere.

When it is not the hormones

Not every headache in a 47-year-old woman is hormonal, and treating the hormones will not fix the ones that are not. Sleep debt, untreated sleep apnoea, alcohol, dehydration, caffeine withdrawal, neck and jaw problems, and medication-overuse headache from frequent painkiller use all worsen in the same decade for unrelated reasons. The last is easy to miss and gets worse the more it is treated.

Bottom line

Hormonal migraine is a response to falling estrogen rather than to estrogen itself, which is why perimenopause — the phase of the largest and most erratic swings — is when it typically worsens. Steady transdermal estradiol given continuously smooths the gradient and reduces attacks for most women with hormonally driven migraine; oral delivery and cyclical regimens can do the opposite by rebuilding the withdrawal that triggers them. Aura requires an individual risk conversation rather than automatic refusal, and new aura on therapy is a reason to stop and be assessed. Track headache days for three months before deciding whether it worked.

Educational content, not medical advice. Laboratory interpretation and any treatment decision are made by a licensed physician after individual evaluation. Individual results vary.